Positive data of subcutaneous Cinryze (Viro Pharma) with Enhanze (Halozyme) delivery platform for HAE

Results of a Phase II subcutaneous trial of Cinryze (C1 esterase inhibitor), from Viro Pharma, in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), showed positive results in patients with Hereditary Angio-oedema (HAE). This open-label, multiple-dose Phase II study was conducted in 12 subjects with HAE who previously participated in the Viro Pharma trial evaluating the pharmacokinetics of subcutaneous injections of Cinryze when given alone relative to intravenous infusion. The data demonstrate that subcutaneous co-administration of Cinryze with rHuPH20 was well tolerated with no serious adverse events, that it delivers physiologically relevant C1 INH functional concentrations (resulting in mean C1 INH functional concentrations greater than or equal to 0.4U/mL for 92 percent of the 72 hour post dosing period as compared to 73 percent for 1000U IV) and it resulted in a statistically significant increase in bioavailability of C1 INH antigen relative to Cinryze 2000U alone. Data was presented at the 2012 annual meeting of the American Academy of Allergy Asthma & Immunology.